The recent, and quite rapid, approval of Gilead Sciences, Inc.’s Veklury (remdesivir) highlights the agency’s willingness to prioritize therapies for emerging infectious disease threats.
Veklury cleared the agency on 22 October 2020, just 77 days after NDA submission for treatment of COVID-19 requiring hospitalization....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?